GLP-1s alter taste perception and commonly disrupt the perception of sweetness, bitterness, fatty foods and even mouthfeel, especially during early treatment phases, says the firm, which has been conducting ongoing research into the food preferences of consumers on the weight loss and diabetes management medications
Protein kinase C inhibitor prevents renal apoptotic and fibrotic changes in response to partial ureteric obstruction
The drug belongs to a new class of GLP-1 medicines that help reduce appetite
The formulation combines methionine, an essential sulfur-containing amino acid
In preclinical models, researchers observed that abaloparatide treatment was associated with increased bone mineral density, trabecular connectivity, and cortical thickness